KKKristian Karstoft

Kristian Karstoft

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristian Karstoft has a total of 373 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes

    by Mie Dyberg Skandov, Katrine McLain Christensen, Dagmar Abelone Dalin, Janne Unkerskov, Andreas Brønden, Marie Lund, Mikkel Bring Christensen, Kristian Karstoft

    Aim: In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre‐marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed. This study aimed to describe real‐world use of semaglutide, including dose titration, discontinuation patterns and effectiveness on body weight in adults with overweight or obesity treated in primary care. Materials and Methods: This retrospective, observational study included adults prescribed semaglutide for weight management between December 2022 and May 2024 in one general practise in Denmark. The primary outcome was the relative mean change in body weight from baseline to 12‐months follow‐up in individuals who had not discontinued treatment and who had a baseline and a follow‐up weight. Results: A total of 206 individuals were included (76% women; mean age 48 years, standard deviation (SD) 13). Mean baseline body weight was 105 kg (SD 23.8). Twelve months after treatment initiation, 38% ( n = 78) had permanently discontinued semaglutide, whilst 15% ( n = 30) had temporarily discontinued (paused) semaglutide. Approximately 48% ( n = 98) remained on treatment. Amongst these, 40% were treated with ≤ 1.0 mg/week, 30% with 1.7 mg/week and 30% with 2.4 mg/week. Relative mean body weight change after 12 months was −13.6 (95% CI −15.0 to −12.2)%. Conclusions: Based on the experience from utilisation in a single general practise, semaglutide for weight management is frequently discontinued and titrated slower and to lower maintenance doses in real‐world clinical practise than in the approved labelling. Despite this, the observed mean weight loss for individuals who had not discontinued treatment was substantial.


  • Open Access

    (Dis)agreement and concordance of metabolic indices from the oral glucose tolerance test and mixed‐meal tolerance test: Implications for application

    by Nina Sloth Nielsen, Nikolaj Agerlin, Nikolas Antoniou, Helga Ellingsgaard, Kristian Karstoft, Louise Lang Lehrskov, Grit Elster Legård, Mark Preben Printz Lyngbæk, Beckey Trinh, Thomas P. J. Solomon, et al.

    Metabolic indices derived from the oral glucose tolerance test (OGTT) and mixed‐meal tolerance test (MMTT) are often interpreted interchangeably; however, these tests represent distinct physiological stimuli. In order to examine potential differential metabolic responses to these tests, we characterized the (dis)agreement between OGTT‐ and MMTT‐derived indices of insulin sensitivity, insulin secretion and β‐cell function. We also described their convergent validity in individuals with normal glucose tolerance (NGT) or type 2 diabetes (T2D). We conducted a post hoc analysis of eight trials with participants who underwent either OGTT or MMTT, or both. Insulin sensitivity, insulin secretion and β‐cell function were derived. Agreement was assessed using Bland–Altman regression approaches to estimate systematic and proportional bias and 95% limits of agreement. Linear mixed‐effects models were used to estimate means by glycaemic status (NGT vs. T2D), and area under the receiver operating characteristic (AUROC) curve analyses were used to evaluate discriminative ability between glycaemic status for the respective test indices. No systematic bias was observed. Proportional bias was present for insulin secretion and β‐cell function, with increasingly negative differences between methods (OGTT–MMTT) as outcome values increased. All indices exhibited relatively wide 95% limits of agreement, which widened further at higher magnitudes. The OGTT‐ and MMTT‐derived means were significantly different between NGT and T2D. We did not observe differences in AUROC between tolerance tests. Agreement between OGTT‐ and MMTT‐derived indices worsened as the respective value increased, suggesting differential stimulus–response characteristics in insulin secretion between tolerance tests. Despite this, descriptive analyses suggest that the test‐specific indices demonstrate convergent validity.

  • Open Access

    The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin—A Randomized, Controlled, Crossover Study

    by Liva K. Stuhr, Joshua B. Feinberg, Thea Christoffersen, Konstantinos Dimopoulos, Mikkel B. Christensen, David P. Sonne, Troels Riis, Peter S. Plomgaard, Jens P. Goetze, Emil L. Larsen, et al.

    Exercise increases blood and lymph flow in working muscles, potentially affecting the bioavailability and effect of subcutaneously administered drugs. The aim of this study was to assess the influence of a single exercise session on pharmacokinetics and pharmacodynamics of a single dose of subcutaneously administered unfractionated heparin. In a crossover design, 15 healthy males underwent four experimental days where 15,000 IU of unfractionated heparin was injected subcutaneously into the thigh of the non‐dominant leg. Following the injection, one of four interventions was performed in randomized order on four separate occasions, each lasting 1 h: (1) no exercise, (2) double‐legged exercise, (3) single‐legged exercise with the non‐dominant leg (where heparin was injected), and (4) single‐legged exercise with the dominant leg. Blood was sampled during and after the interventions and analyzed for activated partial thromboplastin time (aPTT) and plasma heparin via an anti‐factor Xa assay. The primary endpoint (maximum aPTT minus baseline aPTT) showed no statistically significant differences between interventions, nor did maximum minus baseline plasma heparin activities. However, after 1 h, change in aPTT was greater, following double‐legged exercise compared with no exercise (mean difference 3.5 s, 95% CI 0.8–6.2) and greater after single‐legged exercise with the non‐dominant leg compared with the dominant (9.7 s, 3.9–15.5). Similar results were observed for plasma heparin activities. In conclusion, exercise does not affect the overall pharmacokinetics and pharmacodynamics of unfractionated heparin but tends to accelerate absorption and hence effect. The study thus underscores that physical exercise affects temporal uptake of subcutaneously administered therapy.

  • Health benefits of interval walking training

    by Kristian Karstoft, Ida Kær Thorsen, Jens Steen Nielsen, Thomas Phillip James Solomon, Shizue Masuki, Hiroshi Nose, Mathias Ried-Larsen

    Interval walking training (IWT) is a free-living training intervention involving alternating fast and slow walking cycles. IWT is efficacious in improving physical fitness and muscle strength, and reducing factors associated with lifestyle-related diseases. In individuals with type 2 diabetes, IWT improves glycemic control directly through enhanced glucose effectiveness, challenging conventional views on mechanisms behind training-induced improvements in glycemic control. Whereas adherence to IWT in short-term studies is high, ensuring long-term adherence remains a challenge, particularly in populations with chronic diseases and/or overweight/obesity. Long-term studies in real-world settings are imperative to ascertain the widespread effectiveness of IWT and elucidate its impact on hard endpoints.


  • Open Access

    Healthcare professionals' experiences with the use of antipsychotics in dementia

    by Sidsel Maria Jørgensen, Laura Victoria Jedig Lech, Charlotte Vermehren, Michaela L. Schiøtz, Jon Trærup Andersen, Kristian Karstoft, Tina Andersen, Stine Vest Hansen, Hanne Birke


  • Open Access

    Protocol for DEprescribing and Care to reduce Antipsychotics in Dementia (DECADE)–A hybrid effectiveness-implementation pilot study

    by Kirstine Skov Benthien, Laura Victoria Jedig Lech, Hanne Birke, Sidsel Maria Jørgensen, Tina Andersen, Stine Vest Hansen, Jon Trærup Andersen, Kristian Karstoft, Michaela Schiøtz, Charlotte Vermehren

    Introduction: Behavioural and psychological symptoms of dementia (BPSD) should only rarely and briefly be treated with antipsychotics. Despite recommendations to the contrary, the use of antipsychotics in nursing home residents with dementia is widespread and followed by serious adverse effects. Intervention studies on methods to reduce the use of antipsychotics in persons with dementia are few and needed. The aim of this protocol is to describe the rationale and content of the intervention DEprescribing and Care to reduce Antipsychotics in DEmentia (DECADE)–a hybrid effectiveness-implementation pilot study. Materials and methods: This is a protocol of a prospective hybrid effectiveness-implementation pilot study. The primary aim of DECADE is to reduce the use of antipsychotic drugs by 50% in 50% of nursing home residents with dementia while maintaining or improving BPSD. The intervention is implemented in six nursing homes including approximately 190 residents with dementia and consists of Academic Detailing, medication review, education of nursing home staff, and care plans. The evaluation of feasibility and potential effectiveness is an overall assessment of all clinical and process outcomes. Logistic regression analyses will be used to investigate factors characterizing situations with prescription of antipsychotics. BPSD is analysed with a before- and after design using self-controlled case series methods and the use of antipsychotics is analysed as interrupted time series. Discussion: This protocol describes a study that will provide an indication of DECADE effectiveness and a model for upscaling and further evaluation in a controlled design.


  • Open Access

    Redox state and altered pyruvate metabolism contribute to a dose-dependent metformin-induced lactate production of human myotubes

    by Jennifer Maurer, Xinjie Zhao, Martin Irmler, Anders Gudiksen, Nanna S. Pilmark, Qi Li, Thomas Goj, Johannes Beckers, Martin Hrabě de Angelis, Andreas L. Birkenfeld, et al.

    Metformin shifts the equilibrium of lactate dehydrogenase (LDH) reaction by low dose-induced phosphorylation of pyruvate dehydrogenase (PDH) resulting in inhibition of pyruvate oxidation and high dose-induced increase in NADH, which explains the dose-dependent lactate production of differentiated human skeletal muscle cells.


  • The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour: A post-hoc analysis of the PRE-D trial

    by Kristian Karstoft, Mathias Ried-Larsen, Lea Bruhn, Nanna Skytt Pilmark, Katrine Bagge Hansen, Frederik Persson, Marit Eika Jørgensen, Martin Bæk Blond, Kristine Færch

    Perceived physical exertion is increased when exercise is performed on metformin treatment, but the clinical relevance of this is unknown. In this post hoc analysis of a randomized, controlled trial, we investigated whether metformin treatment was associated with lower levels of free-living physical activity. Ninety individuals with overweight/obesity (BMI>25 m(2)/kg) and HbA(1)c-defined prediabetes (39-47 mmol/mol) were randomized to treatment with dapagliflozin (SGLT2-inhibitor; 10 mg once daily, n=30), metformin (850 mg twice daily, n=30) or no treatment (control, n=30) for 13 weeks in a parallel-group, open-label trial. Before (baseline), during (6 weeks) and immediately after (13 weeks) cessation of treatment, a 6-day assessment of physical activity and sedentary behaviour was performed using accelerometer-based physical activity monitors. Intention-to-treat analyses revealed no within-group changes or differences in change between the groups for any measures of physical activity or sedentary behaviour at neither 6 nor 13 weeks. Short-term metformin treatment does not reduce free-living physical activity level in individuals with overweight/obesity and HbA(1)c-defined prediabetes.

  • Open Access

    Adding Different Exercise Training Volumes to a Diet-Induced Weight Loss Facilitates Fat Loss and Maintains Fat-Free Mass in a Dose-Depending Fashion in Persons with Newly Diagnosed Type 2 Diabetes: Secondary Findings from the DOSE-EX Multi-Arm, Parallel-Group, Randomized Trial

    by Mark P.P. Lyngbæk, Grit Elster Legaard, Nina Sloth Nielsen, Cody Garrett Durrer, Thomas Peter Almdal, Morten Asp Vonsild Lund, Benedikte Liebetrau, Caroline Ewertsen, Carsten Lauridsen, Thomas P.J. Solomon, et al.

    OBJECTIVE: To assess the dose-response effects of exercise in combination with a diet-induced weight loss on fat mass (FM) percentage (FM%) in persons with diagnosed type 2 diabetes. RESEARCH DESIGN AND METHODS: In this secondary analysis of a four-armed randomized trial ( Clinicaltrials.gov NCT03769883 ) 82 persons (35% females, mean age and standard deviation (SD) 58.2 (9.8) years) living with type 2 diabetes were randomly allocated to the control group (N=21, CON), diet control (25% energy restriction; N =20, DCON), diet control and exercise three times/week (two sessions of aerobic and one session combining resistance and aerobic training; N =20, MED), or diet control and exercise six times/week (four sessions of aerobic and two sessions combining resistance and aerobic training; N =21, HED) for 16 weeks. The primary outcome was the change in FM percentage points (pp). Secondary outcomes included fat-free mass and visceral adipose tissue volume. RESULTS: Type 2 diabetes duration was 4.0 years (interquartile range 1.9 to 5.5), body weight (SD) 101.4 kg (14.6), FM% (SD) 39.4 (6.7). FMpp decreased compared to standard care −3.5 pp (95% CI −5.6 to −1.4) p=0.002, −6.3 pp (CI −8.4 to −4.1) p<0.001, and −8.0 pp (95% CI −10.2 to −5.8) p<0.001, for DCON, MED, and HED, respectively. The difference between HED and MED was −1.8 pp [95% CI −3.9 to 0.4]; p=0.11). CONCLUSIONS: All interventions were superior in reducing FMpp compared to standard care in a dose-dependent manner. Adding three or six sessions of exercise to a low-calorie diet was superior in reducing FM compared to a low-calorie diet alone. Article Highlights: Why did we undertake this study? Exercise and weight loss are recommended for persons with type 2 diabetes. It is unclear if adding exercise, and which amount of exercise, to a low-calorie diet supports additional fat mass loss. What is the specific question(s) we wanted to answer? What is the dose-response effect of exercise combined with a moderate caloric restriction on changes in fat mass? What did we find? Adding exercise to a diet-induced weight loss reduced fat mass and preserved fat-free mass in a dose-dependent manner. What are the implications of our findings? Adding exercise to a moderate caloric restriction dose-dependently facilitates reductions in fat mass by enlarging weight loss and fat loss.